The global burden of chronic liver disease caused by persistent infection w
ith hepatitis B and C viruses has meant the urgent development of therapeut
ic strategies designed to control active replication and therefore prevent
subsequent clinical sequelae. Advances in these therapeutic strategies are
now clearly happening, mainly as a consequence of a better understanding of
the viral life cycle and the unique pathogenesis of each disease. Further
progress should continue as further insights into the virus-cell relationsh
ip are derived, which will sharpen attention on specific viral targets as w
ell as shift and enhance host cytokine responses. (C) 2000 Blackwell Scienc
e Asia Pty Ltd.